Furthermore, the density of CD4+ GzmB+ T cells in the central region of the tumor is an independent predictor of prognosis in pMMR CRC patients and can also predict the outcome of patients after neoadjuvant chemotherapy. The gene discussed is CD4; the disease is neoplasm.